Follow-up of differentiated thyroid carcinoma

Area of Science:

• Endocrinology
• Oncology
• Nuclear Medicine

Background:

• Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy, primarily papillary or follicular types.
• Standard treatment involves total thyroidectomy, radioactive iodine ablation, and L-thyroxine therapy.
• Management strategies, including surgical extent, radioiodine use, and TSH suppression, are debated regarding recurrence risk.

Purpose of the Study:

• To outline current objectives and advances in the follow-up of differentiated thyroid carcinoma (DTC).
• To evaluate the role of recombinant human TSH (rhTSH) in detecting persistent or recurrent DTC.
• To define optimal follow-up protocols based on recurrence risk.

Main Methods:

• Utilizing neck ultrasound (US), serum thyroglobulin (Tg) measurement, and (131)I total body scans (TBS) after TSH stimulation for disease detection.
• Comparing the efficacy of rhTSH administration versus L-thyroxine withdrawal for TSH stimulation.
• Assessing ultrasensitive Tg measurement methods and their correlation with disease status.

Main Results:

• rhTSH administration and L-thyroxine withdrawal yield equivalent results in detecting recurrent DTC.
• rhTSH use mitigates hypothyroid symptoms and associated systemic effects compared to L-thyroxine withdrawal.
• For low-risk DTC patients, serum Tg after TSH stimulation combined with neck US is effective for monitoring, potentially obviating the need for low-sensitivity TBS.

Conclusions:

• Follow-up protocols for DTC should be risk-stratified and adapted to individual patient needs.
• rhTSH offers a favorable alternative for TSH stimulation in DTC follow-up, improving patient tolerance.
• Achieving undetectable serum Tg post-TSH stimulation and negative neck US indicates remission in low-risk DTC patients.